^
    Apply
    Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (NCT02905188)
    Phase 1
    Baylor College of Medicine
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    03/28/2019
    Primary completion :
    11/17/2021
    Completion :
    01/06/2023
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • GLYCAR T cells • cyclophosphamide intravenous
    Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (NCT04715191)
    Phase 1
    Baylor College of Medicine
    Not yet recruiting
    Last update posted :
    05/06/2024
    Initiation :
    07/03/2024
    Primary completion :
    08/01/2026
    Completion :
    07/03/2041
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • GLYCAR T cells • GPC3-CAR and IL15 plus IL21 • cyclophosphamide intravenous
    Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (NCT04377932)
    Phase 1
    Baylor College of Medicine
    Recruiting
    Last update posted :
    07/07/2023
    Initiation :
    12/08/2021
    Primary completion :
    02/01/2025
    Completion :
    02/01/2040
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • AGAR T cells • GLYCAR T cells • cyclophosphamide intravenous
    T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) (NCT04093648)
    Phase 1
    Baylor College of Medicine
    Withdrawn
    Last update posted :
    05/20/2020
    Initiation :
    01/01/2020
    Primary completion :
    02/01/2023
    Completion :
    01/01/2038
    GPC3
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • GLYCAR T cells • cyclophosphamide intravenous